Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
1.150
-0.020 (-1.71%)
Oct 31, 2024, 4:00 PM EDT - Market closed

Company Description

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.

The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease.

It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer’s disease.

The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019.

Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Alterity Therapeutics Limited
Alterity Therapeutics logo
Country Australia
Founded 1997
Industry Biotechnology
Sector Healthcare
Employees 10
CEO David Stamler

Contact Details

Address:
350 Collins Street, Suite 4
Melbourne, VIC 3000
Australia
Phone 61 3 9349 4906
Website alteritytherapeutics.com

Stock Details

Ticker Symbol ATHE
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency AUD
CIK Code 0001131343
CUSIP Number 02155X106
ISIN Number US02155X2053
SIC Code 2834

Key Executives

Name Position
Dr. David A. Stamler M.D. Chief Executive Officer
Geoffrey Paul Kempler B.Sc. Co-Founder and Non-Executive Chairman
Dr. Rudolph Emile Tanzi Ph.D. Chief Scientific Advisor and Member of Research and Development Advisory Board
Dr. Steven D. Targum M.D. Chief Medical Advisor
Dr. Robert Cherny Head of Research
Phillip Allen Hains BBus(Acc), C.A., M.B.A. Company Secretary

Latest SEC Filings

Date Type Title
Oct 31, 2024 6-K Report of foreign issuer
Oct 23, 2024 6-K Report of foreign issuer
Oct 15, 2024 6-K Report of foreign issuer
Oct 11, 2024 6-K Report of foreign issuer
Oct 4, 2024 6-K Report of foreign issuer
Oct 2, 2024 6-K Report of foreign issuer
Sep 30, 2024 6-K Report of foreign issuer
Sep 26, 2024 20-F Annual and transition report of foreign private issuers
Sep 26, 2024 6-K Report of foreign issuer
Sep 26, 2024 6-K Report of foreign issuer